Dr. Darin Furgeson is a new Assistant Professor in the Department of Pharmaceutics and Pharmaceutical Chemistry, and also a new member of the Nano Institute of Utah. Furgeson returns to the University of Utah by way of Duke University (two years at as a Post Doctoral Fellow) and University of Wisconsin-Madison (four years as an Assistant Professor). He received his BS and ME in Chemical Engineering and Ph.D. in Pharmaceutics and Pharmaceutical Chemistry, all from the University of Utah.
Furgeson’s research is focused in two primary areas: 1) Interventional Oncology and 2) Nanotoxicology. Both involve nanomaterials synthesis and characterization, in vitro testing for bioactivity, and extension to preclinical in vivo models for therapy. First, his research group has designed a recombinant, protein-based drug delivery platform for multi-modal therapy of primary tumors and oligometastases. Second, his group is developing a zebrafish embryo model to accurately gauge systemic toxicity for nanomaterials and to identify physicochemical properties (e.g. size, shape, charge, etc.) affording lower incidences of toxic effects. Furgeson’s research support comes in part from the Nanotechnology Characterization Laboratory (NCL) at National Cancer Institute (NCI)-Frederick. We are excited to welcome Dr. Furgeson to campus, to the Nano Institute, and look forward working with him.
For more information regarding Dr. Furgeson, click here to view his member profile.
